Skip to main content

The Merck and Company Pharmaceutical and Services building in Duluth, Georgia.

TAMI CHAPPELL/REUTERS

Cardiome Pharma Corp. is cutting 85 per cent of its workers as it eliminates all of those focused on internal research and certain support functions.

The move comes after the global pharmaceutical giant Merck & Co. Inc. said earlier this year it was terminating development of the oral version of a heart medication with Cardiome.

An intravenous version of Cardiome's flagship product is marketed as Brinavess IV, which is approved in Europe for treating abnormal heart rhythm in adult patients.

Story continues below advertisement

Vancouver-based Cardiome said Monday it expects up to $5-million in severance and other charges related to the restructuring over the remainder of the year.

"We believe this action was necessary to maximize shareholder value by effective management of Cardiome's cash resources and continued focus on our ongoing partnership with Merck on Brinavess IV," Cardiome interim chief executive William Hunter said in a statement.

Cardiome lost $27.9-million or 56 cents per share in 2011, compared with a profit of $35.5-million or 58 cents per share for the year ended Dec. 31, 2010.

The loss for fiscal 2011 was largely due to spending on clinical development efforts, pre-clinical research projects and other normal operating costs. The net income for fiscal 2010 was largely due to recognition of a $30-million milestone payment from Merck related to a marketing approval in Europe.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies